Please Wait a Moment
X

Articles

23Jul

CTS conversion to the Ortho VERSEIA Integrated Processor (VIP) in January 2021

23 Jul, 2020 | Return|

After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.

Read all about it on the Communication page by clicking this link: Communications

Related

IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization

IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization

Read More >

Spotlight on CTS AABB Annual Meeting Abstract Posters

CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...

Read More >

FDA Guidance ZIKV Testing Strategy Webinar

On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...

Read More >

Convalescent Plasma Testing for COVID-19

CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...

Read More >

Renewed licenses now available on the website

As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....

Read More >

Reminder- The CTS Reentry form- CTS-00172 implements 7/2/18

Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...

Read More >